JO3330B1 - الأجسام المضادة cgrp - Google Patents

الأجسام المضادة cgrp

Info

Publication number
JO3330B1
JO3330B1 JOP/2011/0177A JOP20110177A JO3330B1 JO 3330 B1 JO3330 B1 JO 3330B1 JO P20110177 A JOP20110177 A JO P20110177A JO 3330 B1 JO3330 B1 JO 3330B1
Authority
JO
Jordan
Prior art keywords
cgrp
antibodies
cgrp antibodies
antigen
binding fragment
Prior art date
Application number
JOP/2011/0177A
Other languages
English (en)
Inventor
Allan Barrett
Jan Benschop Robert
James Darling Ryan
Geoffrey Chambers Mark
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of JO3330B1 publication Critical patent/JO3330B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57527—Calcitonin gene related peptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يقدم الاختراع الحالي أجسام مضادة بشرية معدلة وراثيًا للببتيد المرتبط بجين كالسيتونين (CGRP) أو شظية الارتباط بمولد الضد منها. بالإضافة إلى ذلك، يقدم الاختراع الحالي استخدام الأجسام المضادة البشرية المعدلة وراثيًا للببتيد المرتبط بجين كالسيتونين (CGRP) أو شظية الارتباط بمولد الضد منها وذلك لعلاج ألم الالتهاب العظمي المفصلي.
JOP/2011/0177A 2010-06-10 2011-05-31 الأجسام المضادة cgrp JO3330B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35332310P 2010-06-10 2010-06-10

Publications (1)

Publication Number Publication Date
JO3330B1 true JO3330B1 (ar) 2019-03-13

Family

ID=45096388

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2011/0177A JO3330B1 (ar) 2010-06-10 2011-05-31 الأجسام المضادة cgrp

Country Status (33)

Country Link
US (3) US9073991B2 (ar)
EP (2) EP2579894B1 (ar)
JP (2) JP6021806B2 (ar)
KR (1) KR101489566B1 (ar)
CN (2) CN104292332B (ar)
AR (1) AR081434A1 (ar)
AU (1) AU2011265050B2 (ar)
BR (1) BR112012031501B1 (ar)
CA (1) CA2802102C (ar)
CY (2) CY1119789T1 (ar)
DK (1) DK2579894T3 (ar)
EA (1) EA022931B1 (ar)
ES (2) ES2656000T3 (ar)
HR (1) HRP20171992T1 (ar)
HU (2) HUE038135T2 (ar)
IL (2) IL222885B (ar)
JO (1) JO3330B1 (ar)
LT (2) LT2579894T (ar)
LU (1) LUC00112I2 (ar)
ME (1) ME02862B (ar)
MX (2) MX363209B (ar)
NL (1) NL300979I2 (ar)
NO (2) NO2579894T3 (ar)
NZ (1) NZ603607A (ar)
PL (1) PL2579894T3 (ar)
PT (1) PT2579894T (ar)
RS (1) RS56638B1 (ar)
SG (1) SG185648A1 (ar)
SI (1) SI2579894T1 (ar)
TW (1) TWI423818B (ar)
UA (1) UA109658C2 (ar)
WO (1) WO2011156324A1 (ar)
ZA (1) ZA201208996B (ar)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3045182T1 (en) 2005-11-14 2018-08-31 Teva Pharmaceuticals International Gmbh An antibody to a peptide-associated peptide antagonist to calcitonin for treating a headache in aggregates
KR101304150B1 (ko) 2008-03-04 2013-09-05 라브리스 바이올로직스 인코포레이티드 만성 통증의 치료 방법
BR112012004464B8 (pt) 2009-08-28 2021-05-25 Labrys Biologics Inc uso de um anticorpo antagonista anti-cgrp para preparar uma composição farmacêutica para tratar e/ou prevenir dor visceral e/ou um ou mais sintomas de dor visceral, em que a dor visceral está associada á cistite intersticial (ic), e dita composição farmacêutica
JO3330B1 (ar) * 2010-06-10 2019-03-13 Lilly Co Eli الأجسام المضادة cgrp
EA033109B1 (ru) 2011-05-20 2019-08-30 Олдербайо Холдингз Ллк Способы ингибирования, профилактики или лечения диареи и/или поддержания соответствующих уровней электролитов и жидкости в толстой кишке субъекта, подвергающегося связанному с диареей состоянию, с помощью антитела против cgrp или фрагмента антитела против cgrp
PT3495392T (pt) 2011-05-20 2021-09-22 H Lundbeck As Composições anti-cgrp e a sua utilização
CN108014334B (zh) 2011-05-20 2021-11-30 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
MX378344B (es) 2014-03-21 2025-03-10 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
JP6581656B2 (ja) 2014-10-24 2019-09-25 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． グルカゴンおよびｇｌｐ−１受容体のコアゴニスト
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
TWI728953B (zh) 2015-04-24 2021-06-01 美商安美基公司 治療或預防偏頭痛之方法
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
JP6592600B2 (ja) * 2015-10-30 2019-10-16 イーライ リリー アンド カンパニー 抗ｃｇｒｐ／抗ｉｌ−２３二重特異性抗体及びその使用
CN105483091A (zh) * 2015-12-29 2016-04-13 天津三箭生物技术股份有限公司 小鼠抗人Calcitonin单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株
WO2017132062A1 (en) * 2016-01-28 2017-08-03 Eli Lilly And Company Cgrp antibodies and uses thereof
CN108601833B (zh) 2016-02-01 2022-11-15 伊莱利利公司 甲状旁腺激素-抗rankl抗体融合化合物
KR20230047507A (ko) 2016-06-27 2023-04-07 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 암 치료 조합
EP3515488A1 (en) 2016-09-23 2019-07-31 Teva Pharmaceuticals International GmbH Treating cluster headache
SMT202600087T1 (it) * 2016-09-23 2026-03-09 Teva Pharmaceuticals Int Gmbh Trattamento dell’emicrania refrattaria
JP7195262B2 (ja) 2017-03-02 2022-12-23 ベス イスラエル デアコネス メディカル センター インコーポレイティッド カルシトニン遺伝子関連ペプチドを指向する抗体に応答性の頭痛患者の選択方法
AR111845A1 (es) 2017-05-03 2019-08-28 Lilly Co Eli Anticuerpos biespecíficos anti-cgrp / anti-il-23 y usos de los mismos
JP2020525445A (ja) * 2017-06-21 2020-08-27 セファロン・インコーポレイテッドＣｅｐｈａｌｏｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ カチオン交換クロマトグラフィーの洗浄緩衝液
TWI754772B (zh) * 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
JP7339262B2 (ja) 2018-01-12 2023-09-05 アムジェン インコーポレイテッド Ｐａｃ１抗体及びその使用
WO2019231800A1 (en) 2018-05-31 2019-12-05 Eli Lilly And Company Anti-cgrp antibodies for treating menstrual-related migraines
JP2021534197A (ja) 2018-08-22 2021-12-09 イーライ リリー アンド カンパニー 治療抵抗性患者のための抗ｃｇｒｐ抗体
CR20210373A (es) 2019-01-08 2021-08-19 H Lundbeck As Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp
GEAP202515803A (en) 2019-05-02 2025-06-10 H Lundbeck As Treatment of headache using anti-cgrp antibodies
EP3744400A1 (en) * 2019-05-28 2020-12-02 Etablissement Français du Sang Car-t cells targeting il-1rap and their use in acute myeloid leukemia (aml)
CN114127110B (zh) * 2019-05-30 2022-07-01 山东博安生物技术股份有限公司 抗cgrp抗体及其应用
EP4045641A1 (en) 2019-10-15 2022-08-24 Eli Lilly and Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
KR20210124867A (ko) 2020-04-06 2021-10-15 하. 룬드벡 아크티에셀스카브 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료
JP2024509165A (ja) 2021-03-02 2024-02-29 シージーアールピー ダイアグノスティクス ゲーエムベーハー 片頭痛の治療及び／又は発生の低減
CN119136838A (zh) 2022-02-28 2024-12-13 特瑞德姆生物科技有限责任两合公司 由至少一种β-葡聚糖或甘露聚糖组成或包含至少一种β-葡聚糖或甘露聚糖的偶联物
US20260125454A1 (en) * 2022-08-11 2026-05-07 Shanghai Junshi Biosciences Co., Ltd. Anti-cgrp antibody and use
CN118271438B (zh) * 2024-05-27 2024-08-30 上海宏成药业有限公司 抗cgrp抗体或其抗原结合片段及其用途
WO2026098547A1 (zh) * 2024-11-08 2026-05-15 湖北生物医药产业技术研究院有限公司 一种靶向cgrp的抗体及其应用
CN119320450B (zh) * 2024-12-13 2025-07-25 中国人民解放军军事科学院军事医学研究院 针对降钙素基因相关肽的抗体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU668349B2 (en) * 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
EP0590058B1 (en) * 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
JP4976376B2 (ja) 2005-04-08 2012-07-18 メディミューン，エルエルシー 哺乳動物メタニューモウイルスに対する抗体
SI3045182T1 (en) 2005-11-14 2018-08-31 Teva Pharmaceuticals International Gmbh An antibody to a peptide-associated peptide antagonist to calcitonin for treating a headache in aggregates
WO2007076336A1 (en) * 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies
MX2010009724A (es) * 2008-03-04 2010-09-28 Pfizer Ltd Procedimientos de tratamiento del dolor inflamatorio-.
KR101304150B1 (ko) * 2008-03-04 2013-09-05 라브리스 바이올로직스 인코포레이티드 만성 통증의 치료 방법
JO3330B1 (ar) * 2010-06-10 2019-03-13 Lilly Co Eli الأجسام المضادة cgrp

Also Published As

Publication number Publication date
CY2019017I2 (el) 2020-05-29
ES2930321T3 (es) 2022-12-09
LTC2579894I2 (lt) 2020-03-25
BR112012031501B1 (pt) 2020-02-11
AU2011265050A1 (en) 2012-11-08
EA022931B1 (ru) 2016-03-31
NO2579894T3 (ar) 2018-04-21
EA201270769A1 (ru) 2013-04-30
ZA201208996B (en) 2014-05-28
UA109658C2 (xx) 2015-09-25
EP3318272B1 (en) 2022-08-10
US9505838B2 (en) 2016-11-29
PL2579894T3 (pl) 2018-04-30
HRP20171992T1 (hr) 2018-02-09
MX363209B (es) 2019-03-14
TW201210618A (en) 2012-03-16
LUC00112I1 (ar) 2019-04-10
HUS1900020I1 (hu) 2019-05-28
JP6021806B2 (ja) 2016-11-09
EP3318272A1 (en) 2018-05-09
CY1119789T1 (el) 2018-06-27
AU2011265050B2 (en) 2013-06-27
HUE038135T2 (hu) 2018-09-28
LTPA2019011I1 (lt) 2019-05-10
AR081434A1 (es) 2012-08-29
CY2019017I1 (el) 2020-05-29
EP2579894B1 (en) 2017-11-22
NL300979I2 (nl) 2019-07-11
HK1203211A1 (en) 2015-10-23
US20170073403A1 (en) 2017-03-16
CN102946905B (zh) 2014-10-15
CN104292332B (zh) 2019-11-01
IL222885A0 (en) 2012-12-31
US20150259415A1 (en) 2015-09-17
RS56638B1 (sr) 2018-03-30
MX340999B (es) 2016-08-03
JP2013532143A (ja) 2013-08-15
PT2579894T (pt) 2018-02-06
IL242409B (en) 2020-07-30
US9073991B2 (en) 2015-07-07
CA2802102C (en) 2016-07-26
NO2019017I1 (no) 2019-04-05
US20110305711A1 (en) 2011-12-15
KR101489566B1 (ko) 2015-02-03
NL300979I1 (nl) 2019-04-17
ES2656000T3 (es) 2018-02-22
JP2017014203A (ja) 2017-01-19
IL222885B (en) 2019-09-26
SG185648A1 (en) 2012-12-28
TWI423818B (zh) 2014-01-21
EP2579894A1 (en) 2013-04-17
KR20130034024A (ko) 2013-04-04
DK2579894T3 (en) 2018-01-15
WO2011156324A1 (en) 2011-12-15
ME02862B (me) 2018-04-20
EP2579894A4 (en) 2013-12-04
CN104292332A (zh) 2015-01-21
SI2579894T1 (en) 2018-01-31
LUC00112I2 (ar) 2019-12-27
NZ603607A (en) 2014-09-26
LT2579894T (lt) 2018-02-26
JP6466883B2 (ja) 2019-02-06
MX2012014480A (es) 2013-02-07
CA2802102A1 (en) 2011-12-15
BR112012031501A2 (pt) 2016-10-25
CN102946905A (zh) 2013-02-27

Similar Documents

Publication Publication Date Title
MX363209B (es) Anticuerpos de peptido relacionado con el gen calcitonina.
PH12013500277A1 (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
MX355543B (es) Macrociclos peptidomiméticos.
EA201290557A1 (ru) Пептидный аналог оксинтомодулина
NZ587292A (en) Use of anti-CGRP (calcitonin gene-related peptide) antagonists to treat chronic pain
SG194701A1 (en) Anti-cd40 antibodies and methods of use
NZ707086A (en) Anti-cd40 antibodies and methods of use
MX2017016502A (es) Anticuerpos contra cd40 con actividad agonista mejorada.
MX341578B (es) Tratamiento de la osteoartritis y del dolor.
MX2010005651A (es) Inhibicion de receptor de proteina de estimulacion de macrofagos (ron) y sus metodos de tratamiento.
MX2012002464A (es) El uso de anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de la calcitonina para tratar dolor visceral.
NZ626242A (en) Anti-asic1 antibodies and uses thereof
NZ607588A (en) Antibodies against human TWEAK and uses thereof
MX2013001267A (es) ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.
PH12015501360A1 (en) Bmp-6 antibodies
PH12013501205A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
MX341020B (es) Peptidos derivados de lactoferrina humana y su uso.
MX2015002465A (es) Anticuerpos monoclonales para mejorar o inhibir factor de crecimiento 1 similar a insulina (igf-1).
HK1198135A1 (en) Prevention and treatment of pain using antibodies to lysophosphatidic acid
EP2552462A4 (en) CCN3 THERAPEUTIC PEPTIDES AND THEIR ANALOGS
MY155340A (en) Use of cathepsin c
GB201103780D0 (en) Treatment for ige-mediated disease
PH12013500432A1 (en) Anti-vegfr-3 antibody compositions
MX2013003168A (es) Anticuerpo contra ephrin b2 y su uso.
MX2013011629A (es) Uso de un agente que consiste en anticuerpos y/o antagonistas de factor de crecimiento tipo insulina.